Aviragen Therapeutics (AVIR) Misses Q4 EPS by 4c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.47), $0.04 worse than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Abivax reports Phase 3 maintenance trial results for obefazimod
• Barclays Starts Hawkins (HWKN) at Equalweight